Kiniksa Pharmaceuticals CEO Sanj K. Patel Exercises Options and Sells Shares Under 10b5-1 Plan

Sanj K. Patel, Chairman & CEO of Kiniksa Pharmaceuticals International, executed significant transactions on May 1, 2026. He exercised 48,565 share options at $30.93 per share and immediately sold the same number of Class A Ordinary Shares at a weighted average price of $54.02 per share, resulting in a substantial gain. The transactions were executed pursuant to a 10b5-1 trading plan established on October 31, 2025. Following these transactions, Patel no longer holds any shares directly but maintains indirect ownership through three family trusts totaling 237,763 shares. The option exercised was fully vested with an expiration date of September 19, 2028. This represents a routine exercise and sale under a pre-established trading plan by the company's top executive.